BOSTON & MONTREAL, November 04, 2025--enGene Holdings Inc. ("enGene" or the "Company") (Nasdaq: ENGN), a clinical-stage, ...
ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.
The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...
Johnson & Johnson has brought its bladder cancer drug TAR-200 to the US market, a year after its prospects were dented by a negative phase 3 readout. The novel formulation of the stalwart ...
Announces NDV-01 9-Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a ...
Bacillus Calmette-Guérin (BCG) shortages and the fragile BCG supply chain have created a bladder cancer treatment vacuum.
The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...
October 2025 proved to be a significant month for the oncology landscape, marked by a wave of key regulatory decisions from ...
For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...
Meet Emma Sheppard, a 42-year-old woman who has undergone surgery 35 times in the past 28 years, with her first operation ...
Meet the woman who has had surgery 35 times in 28 years - first going under the knife when she was just 14. Emma Sheppard, 42 ...
Meet the woman who has had surgery 35 times in 28 years - first going under the knife when she was just 14. Emma Sheppard, 42 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback